Banff 2022 Kidney Commentary: Reflections and Future Directions

Author:

Rabant Marion1,Adam Benjamin A.2,Aubert Olivier3,Böhmig Georg A.4,Clahsen Van-Groningen Marian56,Cornell Lynn D.7,de Vries Aiko P.J.89,Huang Edmund10,Kozakowski Nicolas11,Perkowska-Ptasinska Agnieszka12,Riella Leonardo V.13,Rosales Ivy A.14,Schinstock Carrie15,Simmonds Naomi16,Thaunat Olivier17,Willicombe Michelle18

Affiliation:

1. Department of Pathology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

2. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.

3. Kidney Transplant Department, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

4. Department of Medicine III, Medical University of Vienna, Vienna, Austria.

5. Department of Pathology and Clinical Bioinformatics, Erasmus MC Transplant Institute, Rotterdam, the Netherlands.

6. Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany.

7. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

8. Division of Nephrology, Department of Medicine, Leiden University Medical Center, Leiden, the Netherlands.

9. Leiden Transplant Center, Leiden University Medical Center, Leiden, the Netherlands.

10. Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.

11. Department of Pathology, Medical University of Vienna, Vienna, Austria.

12. Department of Pathology, Medical University of Warsaw, Warsaw, Poland.

13. Nephrology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

14. Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

15. Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN.

16. Department of Pathology, Guys and St Thomas’ NHS Foundation Trust, London, United Kingdom.

17. Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

18. Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom.

Abstract

In September 2022, in Banff, Alberta, Canada, the XVIth Banff meeting, corresponding to the 30th anniversary of the Banff classification, was held, leading to 2 recent publications. Discussions at the Banff meeting focused on proposing improvements to the Banff process as a whole. In line with this, a unique opportunity was offered to a selected group of 16 representatives from the pathology and transplant nephrology community, experts in the field of kidney transplantation, to review these 2 Banff manuscripts. The aim was to provide an insightful commentary, to gauge any prospective influence the proposed changes may have, and to identify any potential areas for future enhancement within the Banff classification. The group expressed its satisfaction with the incorporation of 2 new entities, namely “microvascular inflammation/injury donor-specific antibodies–negative and C4d negative” and “probable antibody-mediated rejection,” into category 2. These changes expand the classification, facilitating the capture of more biopsies and providing an opportunity to explore the clinical implications of these lesions further. However, we found that the Banff classification remains complex, potentially hindering its widespread utilization, even if a degree of complexity may be unavoidable given the intricate pathophysiology of kidney allograft pathology. Addressing the histomorphologic diagnosis of chronic active T cell–mediated rejection (CA TCMR), potentially reconsidering a diagnostic-agnostic approach, as for category 2, to inflammation in interstitial fibrosis and tubular atrophy and chronic active T cell–mediated rejection was also an important objective. Furthermore, we felt a need for more evidence before molecular diagnostics could be routinely integrated and emphasized the need for clinical and histologic context determination and the substantiation of its clinical impact through rigorous clinical trials. Finally, our discussions stressed the ongoing necessity for multidisciplinary decision-making regarding patient care.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3